Amneal Pharmaceuticals, Inc.

Total Valuation

Amneal Pharmaceuticals, Inc. carries a market capitalization of 6.45B, placing it among publicly traded companies globally. Its enterprise value stands at 8.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Amneal Pharmaceuticals, Inc. currently has 319.33M shares outstanding.

Valuation Ratios

Amneal Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 34.76. The price-to-sales ratio is 1.75, and the price-to-book ratio stands at 167.38.

Enterprise Valuation

On an enterprise value basis, Amneal Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 12.16 and an EV/FCF ratio of 12.46. The EV/Sales ratio of 2.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.09 provides insight into valuation relative to core operating earnings.

Financial Position

Amneal Pharmaceuticals, Inc. maintains a current ratio of 2.20, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8,453.73, indicating elevated leverage, while an interest coverage ratio of 2.96 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Amneal Pharmaceuticals, Inc. has paid -14.14M in income taxes, reflecting an effective tax rate of 14.90.

Stock Price Statistics

Amneal Pharmaceuticals, Inc.'s stock has gained approximately 96.24976% over the past 52 weeks. The 50-day moving average sits at 18.63, while the 200-day moving average is 15.43.

Income Statement

Over the trailing twelve months, Amneal Pharmaceuticals, Inc. generated 3.12B in revenue and converted that into 157.36M in net income, yielding earnings per share of 0.66. EBITDA reached 673.53M, while operating income came in at 479.24M.

Balance Sheet

Amneal Pharmaceuticals, Inc. holds 127.64M in cash and equivalents against 2.79B in total debt, resulting in a net debt position of 2.54B. Total book value stands at 33.02M, with working capital of 1.06B providing operational flexibility.

Cash Flow

Amneal Pharmaceuticals, Inc. produced 200.78M in operating cash flow over the past twelve months. After subtracting -213.08M in capital expenditures, free cash flow totaled -12.31M - equivalent to -0.04 per share.

Margins

Amneal Pharmaceuticals, Inc. operates with a gross margin of 39.32, reflecting its pricing power and cost economics. The operating margin of 15.37 and net profit margin of 5.05 provide insight into operational efficiency.

Dividends & Yields

Scores

Amneal Pharmaceuticals, Inc. posts an Altman Z-Score of 2.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.